ESR1 and breast carcinoma: To validate DART-CLQ, we first focused on a well-known cancer gene, TP53. An associated perturbation signature, reflecting TP53 deactivation, was also among the consistent signatures derived in the ER+ subset of breast cancer, resulting in a 35-gene clique module.